Cara Therapeutics Reports First Quarter 2019 Financial Results
– Conference call today at 4:30 p.m. ET –
STAMFORD, Conn., May 07, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus as well as pain by selectively targeting peripheral kappa opioid receptors, today announced financial results and operational highlights for the first quarter ended March 31, 2019.
“We are pleased with the progress made across our clinical pruritus programs in chronic kidney disease in the first quarter and remain on track to release top-line data from KALM-1, the first of our pivotal Phase 3 trials of KORSUVA Injection for chronic kidney disease-associated pruritus in hemodialysis patients, in the second quarter,” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics. “Additionally, we look forward to broadening our clinical pruritus program for Oral KORSUVA with the initiation of Phase 2 trials in chronic liver disease and atopic dermatitis in the next few months.”
First Quarter and Recent Developments:
KORSUVA™ (CR845/difelikefalin) Injection Phase 3 Program: Chronic Kidney Disease-Associated Pruritus (CKD-aP): Hemodialysis
In January 2019, based on the recommendation of the Independent Data Monitoring Committee, the Company announced that its pivotal KALM™-1 Phase 3 trial of KORSUVA Injection will continue as planned with no changes to the original enrollment target of 350 hemodialysis patients with moderate-to-severe CKD-aP. The pre-specified interim conditional power assessment was conducted after approximately half of the targeted number of patients completed the designated 12-week treatment period. The Company also announced the completion of enrollment in the KALM-1 trial, and it expects top-line data from this trial in the second quarter of 2019.
The Company continues to enroll patients in the United States, Europe and Asia Pacific in KALM-2, the global Phase 3 efficacy trial of KORSUVA Injection. Based on current patient enrollment projections, the Company expects top-line data from this trial in the second half of 2019.
The Company’s long term, 52-week open-label Phase 3 safety trial continues to progress. Approximately 150 patients have completed at least 6 months of treatment and approximately 40% of these patients have completed 1 year of treatment.
In the second quarter of 2019, the Company initiated an additional open-label safety trial of KORSUVA Injection that is expected to enroll up to 400 hemodialysis patients with CKD-aP for up to 12 weeks of treatment. Both of the safety trials are expected to support worldwide registration filings of KORSUVA Injection.
Oral KORSUVA: CKD-aP: Non-Hemodialysis
The Company continues to enroll patients in the Phase 2 trial of Oral KORSUVA for the treatment of pruritus in stage III - V (moderate-to-severe) chronic kidney disease, or CKD, patients. Based on current enrollment projections, the Company anticipates top-line data from this trial in the second half of 2019.
Oral KORSUVA: Chronic Liver Disease-Associated Pruritus (CLD-aP)
The Company recently completed a Phase 1 trial of Oral KORSUVA at multiple tablet strengths in patients with chronic liver disease, or CLD. The pharmacokinetic parameters were dose proportional and Oral KORSUVA was generally well tolerated with no unexpected safety signals reported. The Company expects to initiate a Phase 2 trial in CLD patients with moderate-to-severe pruritus in the second quarter of 2019.
Oral KORSUVA: Atopic Dermatitis
The Company plans to initiate a multi-dose, proof-of-concept Phase 2 trial of Oral KORSUVA in atopic dermatitis patients with moderate-to-severe pruritus around mid-year 2019.
Upcoming Activities
The Company expects to make presentations at the following conferences:
- Bank of America Merrill Lynch Health Care Conference 2019, May 14-16, 2019
- Jefferies 2019 Healthcare Conference, June 4-7, 2019
- European Academy of Dermatology and Venereology, October 9–13, 2019
First Quarter 2019 Financial Results
Net Loss: The Company reported a net loss of $22.0 million, or $0.56 per basic and diluted share, for the first quarter of 2019 compared to a net loss of $16.8 million, or $0.51 per basic and diluted share, for the first quarter of 2018.
Revenues: Total revenue was $4.4 million for the three months ended March 31, 2019. There was no revenue during the three months ended March 31, 2018. Total revenue in 2019 consisted of:
- License and milestone fees revenue of $4.2 million that was recognized by the Company related to its license agreement with Vifor Fresenius Medical Care Renal Pharma Ltd.
- Clinical compound revenue of $140,000 that was earned by the Company from the sale of clinical compound to Maruishi Pharmaceutical Co. Ltd.
Research and Development (R&D) Expenses: R&D expenses were $23.6 million for the three months ended March 31, 2019 compared to $13.4 million for the three months ended March 31, 2018. The higher R&D expenses in 2019 were primarily due to a net increase in clinical trial costs, as well as increases in stock compensation expense and payroll and related costs.
General and Administrative (G&A) Expenses: G&A expenses were $3.9 million for the three months ended March 31, 2019 compared to $3.7 million for the three months ended March 31, 2018. The increase in 2019 was primarily due to increases in legal, accounting and consultants’ costs.
Other Income: Other income was $1.1 million for the three months ended March 31, 2019 compared to $311,000 for the three months ended March 31, 2018. The increase in 2019 was due to an increase in interest and accretion income resulting from a higher average balance of the Company’s portfolio of investments in the 2019 period.
Cash and Cash Equivalents and Marketable Securities Position: At March 31, 2019, cash and cash equivalents and marketable securities totaled $156.1 million compared to $182.8 million at December 31, 2018. The decrease in the balance of cash and cash equivalents and marketable securities primarily resulted from cash used in operations of $27.5 million, partially offset by proceeds of $0.2 million from the exercise of stock options.
Financial Guidance
Based on timing expectations and projected costs for current clinical development plans, Cara expects that its existing cash and cash equivalents and available-for-sale marketable securities as of March 31, 2019 will be sufficient to fund its currently anticipated operating expenses and capital expenditures into the fourth quarter of 2020, without giving effect to any potential milestone payments under existing collaborations.
Conference Call
Cara management will host a conference call today at 4:30 p.m. ET to discuss first quarter 2019 financial results and provide a business update.
To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 3027399. A live webcast of the call can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com.
An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus as well as pain by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVATM (CR845/difelikefalin), a first-in-class KOR agonist that targets the body's peripheral nervous system, as well as certain immune cells. In Phase 2 trials, KORSUVA™ Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in pruritus-related quality of life measures in hemodialysis patients with moderate-to-severe CKD-aP and is currently being investigated in Phase 3 trials in hemodialysis patients with CKD-aP.
The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.
Forward-looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the expected timing of the data readouts from the Company’s ongoing clinical trials, the expected timing for initiation of the Company’s planned clinical trials, the potential results of ongoing and planned clinical trials, future regulatory and development milestones for the Company’s product candidates, the potential for the Company’s product candidates to be alternatives in the therapeutic areas investigated, and the Company’s expected cash reach. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Cara Therapeutics’ filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 and its other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cara Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Financial tables follow
| CARA THERAPEUTICS, INC. | |||||||||||
| CONDENSED STATEMENTS OF OPERATIONS | |||||||||||
| (amounts in thousands, except share and per share data) | |||||||||||
| (unaudited) | |||||||||||
| Three Months Ended March 31, | |||||||||||
| 2019 | 2018 | ||||||||||
| Revenue: | |||||||||||
| License and milestone fees | $ | 4,242 | $ | - | |||||||
| Clinical compound revenue | 140 | - | |||||||||
| Total revenue | 4,382 | - | |||||||||
| Operating expenses: | |||||||||||
| Research and development | 23,608 | 13,427 | |||||||||
| General and administrative | 3,908 | 3,697 | |||||||||
| Total operating expenses | 27,516 | 17,124 | |||||||||
| Operating loss | (23,134 | ) | (17,124 | ) | |||||||
| Other income | 1,089 | 311 | |||||||||
| Loss before benefit from income taxes | (22,045 | ) | (16,813 | ) | |||||||
| Benefit from income taxes | 85 | 46 | |||||||||
| Net loss | $ | (21,960 | ) | $ | (16,767 | ) | |||||
| Net loss per share : | |||||||||||
| Basic and Diluted | $ | (0.56 | ) | $ | (0.51 | ) | |||||
| Weighted average shares: | |||||||||||
| Basic and Diluted | 39,552,277 | 32,681,661 | |||||||||
| CARA THERAPEUTICS, INC. | ||||||||||
| CONDENSED BALANCE SHEETS | ||||||||||
| (in thousands) | ||||||||||
| (unaudited) | ||||||||||
| March 31, | December 31, | |||||||||
| 2019 | 2018 | |||||||||
| Assets | ||||||||||
| Current assets: | ||||||||||
| Cash and cash equivalents | $ | 14,188 | $ | 15,081 | ||||||
| Marketable securities | 120,265 | 146,302 | ||||||||
| Income tax receivable | 749 | 664 | ||||||||
| Other receivables | 1,019 | 926 | ||||||||
| Prepaid expenses | 7,577 | 4,805 | ||||||||
| Restricted cash, current | 361 | 361 | ||||||||
| Total current assets | 144,159 | 168,139 | ||||||||
| Operating lease right-of-use asset | 3,492 | - | ||||||||
| Marketable securities, non-current | 21,687 | 21,396 | ||||||||
| Property and equipment, net | 841 | 880 | ||||||||
| Restricted cash | 408 | 408 | ||||||||
| Total assets | $ | 170,587 | $ | 190,823 | ||||||
| Liabilities and stockholders’ equity | ||||||||||
| Current liabilities: | ||||||||||
| Accounts payable and accrued expenses | $ | 13,310 | $ | 13,622 | ||||||
| Operating lease liability, current | 901 | - | ||||||||
| Current portion of deferred revenue | 28,194 | 26,825 | ||||||||
| Total current liabilities | 42,405 | 40,447 | ||||||||
| Operating lease liability, non-current | 4,087 | - | ||||||||
| Deferred revenue, non-current | 9,573 | 15,184 | ||||||||
| Deferred lease obligation | - | 1,562 | ||||||||
| Commitments and contingencies | - | - | ||||||||
| Stockholders’ equity: | ||||||||||
| Preferred stock | - | - | ||||||||
| Common stock | 39 | 39 | ||||||||
| Additional paid-in capital | 430,724 | 428,059 | ||||||||
| Accumulated deficit | (316,314 | ) | (294,354 | ) | ||||||
| Accumulated other comprehensive income (loss) | 73 | (114 | ) | |||||||
| Total stockholders’ equity | 114,522 | 133,630 | ||||||||
| Total liabilities and stockholders’ equity | $ | 170,587 | $ | 190,823 | ||||||
INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations, Inc.
212-362-1200
michael@sternir.com
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com
